Improving IOL power calculations

Article

By using calibrated axial length readings obtained with partial optical coherence interferometry (PCI) and intraocular lens (IOL) power calculation formulas incorporating anterior chamber depth (ACD) prediction algorithms, the accuracy of power calculations can be greatly improved, according to study published in the February issue of Acta Ophthalmologica Scandinavia.

By using calibrated axial length readings obtained with partial optical coherence interferometry (PCI) and intraocular lens (IOL) power calculation formulas incorporating anterior chamber depth (ACD) prediction algorithms, the accuracy of power calculations can be greatly improved, according to study published in the February issue of Acta Ophthalmologica Scandinavia.

Thomas Olsen from the University Eye Clinic, Aarhus Kommunehospital, Aarhus, Denmark, calculated the IOL power for 461 consecutive cataract patients using both PCI and ultrasound. The accuracy of the results from each technique were compared. Predictions were calculated using both a recently published 5–variable method and the Haigis 2–variable method. All calculations were optimized in retrospect to account for systematic errors, including IOL constants and other off–set errors.

The average absolute IOL prediction error (observed minus expected refraction) was 0.65 D with ultrasound and 0.43 D with PCI using 5–variable ACD prediction method (p‹0.00001). The number of predictions within ±0.5 D, ±1.0 D and ±2.0 D of the expected outcome was 62.5%, 92.4% and 99.9% with PCI, compared with 45.5%, 77.3% and 98.4% with ultrasound (p‹0.00001), respectively. The 2–variable ACD method resulted in an average error in PCI prediction of 0.46 D, which was found to be significantly higher than the 5–variable method (p‹0.001).

Olsen concluded that the accuracy of IOL power calculations is significantly improved when using PCI and modern calculation formulas that incorporate the latest generation ACD prediction algorithms.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.